{"id":44260,"date":"2024-03-22T15:33:13","date_gmt":"2024-03-22T19:33:13","guid":{"rendered":"https:\/\/d56fg8tfg.fitnews.club\/finance\/ftc-files-amicus-brief-in-asthma-inhaler-patent-dispute\/"},"modified":"2024-03-22T15:33:13","modified_gmt":"2024-03-22T19:33:13","slug":"ftc-files-amicus-brief-in-asthma-inhaler-patent-dispute","status":"publish","type":"post","link":"https:\/\/d56fg8tfg.fitnews.club\/finance\/ftc-files-amicus-brief-in-asthma-inhaler-patent-dispute\/","title":{"rendered":"FTC Files Amicus Brief in Asthma Inhaler Patent Dispute"},"content":{"rendered":"
The Federal Trade Commission filed an amicus brief<\/a> explaining that pharmaceutical maker Teva has improperly listed patents in the Food and Drug Administration\u2019s (FDA) Orange Book and urged the court to order those listings removed. Improper Orange Book listings can harm competition by delaying the entry of cheaper generic products, according to the FTC\u2019s brief.<\/p>\n The FTC\u2019s amicus brief relates to a case brought by Teva against drugmaker Amneal after Amneal sought FDA approval to bring a generic version of asthma inhaler ProAir HFA to market.<\/p>\n Teva sued Amneal for patent infringement, arguing that Amneal\u2019s patents infringe on Teva\u2019s ProAir HFA patents. Since Teva listed those patents on its ProAir HFA inhaler in the FDA\u2019s publication of \u201cApproved Drug Products with Therapeutic Equivalence Evaluations,\u201d commonly known as the \u201cOrange Book,\u201d Teva\u2019s patent infringement claims triggered a statutory stay that blocks approval of Amneal\u2019s competing drug product for up to 30 months\u2014potentially until February 2026.<\/p>\n Amneal argues that Teva improperly listed its patents in the Orange Book and therefore should not be able to stay approval of Amneal\u2019s competing generic product. Amneal further claims that Teva\u2019s improper listing of these products harmed competition. Absent Teva\u2019s improper Orange Book listings, Amneal claims the FDA could approve its competing product as early as April 2024.<\/p>\n In its amicus brief filed in Teva Branded Pharmaceutical Products R&D, et al. v. Amneal Pharmaceuticals of New York, LLC, et al., the FTC states that the court should grant Amneal\u2019s motion for judgment to compel de-listing the patents at issue in this case. This would clear the way for swifter approval of competing generic products.\u00a0<\/p>\n